Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saridegib + Gemcitabine in Metastatic Pancreatic Cancer
NCT01130142Phase 2Completed
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Apr 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial comparing Saridegib + Gemcitabine with Placebo + Gemcitabine (2 arms). Primary endpoints: Maximum Tolerated Dose and Overall Survival. Started Apr 2010; status: completed.
02
Drugs
patidegib
Beyond the preview
Go deeper on NCT01130142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01130142.